Samples* | Method | RIF | INH | EMB | PYR | STR | ETH | AMK | CAP | FLQ | PAS |
---|
por5 | DST | R | R | R | R | R | R | S | S | S | S |
|
TBProfiler
| R | R | R | R | R | R | S | S | S | S |
|
Mykrobe**
| R | R | R |
82%R
| R | – | S | S | S | – |
por6 | DST | R | R | R | R | R | R | R | R | R | S |
|
TBProfiler
| R | R | R | R | R | R | R | R | R | S |
|
Mykrobe
| R | R | R | R | R | – |
82%R
|
82%R
| R | – |
por7 | DST | R | R | R | R | R | R | R | R | R | S |
|
TBProfiler
| R | R | R | R | R | R |
S
|
S
| R | S |
|
Mykrobe
| R |
92%R
|
S
| R |
83%R
| – |
S
|
S
|
91%R
| – |
- DST drug susceptibility testing (R resistant, S sensitive); this table shows the percentage of replicates producing the correct result; − cannot be determined; bolded values indicate the % of replicates with DST phenotypes, where resistance mutations are not found in all replicates. Underlined values indicate where the variant is not present in software mutation library; RIF rifampicin, INH isoniazid, EMB ethambutol, PYR pyrazinamide, STR streptomycin, ETH ethionamide, AMK amikacin, CAP capreomycin, FLQ fluoroquinolones, PAS para-aminosalicylic acid. *All LAM4 strain-types or sub-lineage 4.3.4.2. **Mykrobe-Profiler TB (https://github.com/iqbal-lab/Mykrobe-predictor) implemented using its command-line version